

Test Request Form

PATIENT INFORMATION (REQUIRED)

Patient Last Name:		Patient First Name:	
Address:			
City:	State:	Zip Code:	
Date of Birth: Date (MM DD YYYY):	Gender:	Phone:	

PATIENT CHARACTERISTICS (REQUIRED)

<p>Nodule Diagnosis (ICD-10 Code):</p> <input type="checkbox"/> R91.1 Solitary pulmonary nodule <input type="checkbox"/> R91.8 Abnormal findings of lung (multiple pulmonary nodules) <input type="checkbox"/> Other: <small>For your convenience, the ICD-10 codes that are used to identify patients with single or multiple nodules are listed. Please report the code(s) that best describe the reason the test is being ordered, whether listed or not.</small>	<p>Enter single dimension Nodule Diameter (mm):</p> <p>Nodule Spiculated?</p> <input type="checkbox"/> Yes <input type="checkbox"/> No
<p>Nodule located in upper lobe?</p> <input type="checkbox"/> Yes <input type="checkbox"/> No	<p>Does the patient have a history of cancer?</p> <input type="checkbox"/> No History of Cancer <input type="checkbox"/> Non-Lung Cancer (diagnosed more than 5 years ago) <input type="checkbox"/> Non-Lung Cancer (diagnosed within 5 years) <input type="checkbox"/> Lung Cancer
<p>Smoking Status:</p> <input type="checkbox"/> Current <input type="checkbox"/> Former <input type="checkbox"/> Non-Smoker	

BILLING INFORMATION (REQUIRED)

Check Only One Box

- Patient insurance information is ATTACHED (Please attach a copy of the patient's insurance card and/or Face Sheet if possible)
- Patient does not have insurance (please complete the financial assistance application included in test kit and attach a copy)

Biodesix will bill for the Nodify XL2 test using CPT code 0080U and for the Nodify CDT test using CPT code 81599.

TEST MENU (REQUIRED)

Select the box next to Nodify Lung™ Nodule Risk Assessment to order full test offering, or check the individual options below to order tests individually

- Nodify Lung™ Nodule Risk Assessment Testing**
 The Nodify CDT test (CDT) will be performed before the Nodify XL2 test (XL2) **unless:**
 the CDT result is positive **OR** the pre-test risk is 50%-65%, then the CDT result is delivered and XL2 is not performed **OR** the pre-test risk is >65%, then the primary contact will be notified that neither test will be performed
- Nodify XL2® Proteomic Test Only**
- Nodify CDT™ Proteomic Test Only**

The pre-test risk of malignancy according to the Solitary Pulmonary Nodule (SPN) Calculator. The SPN Calculator was not validated for patients with a previous diagnosis of lung cancer or non-lung cancer within 5 years.¹ Nodify Testing is intended for patients who are at least 40 years of age with an incidental nodule between 8-30mm. The Nodify XL2 test is intended for patients with a pre-test risk of malignancy of 50% or less. The Nodify CDT test is intended for patients with a pre-test risk of malignancy of 65% or less and no previous diagnosis of cancer (except basal cell carcinoma).

DIAGNOSTIC PLAN (IF APPLICABLE)

Prior to receiving test results, which procedures are you considering for this patient (check all that apply)

- | | |
|---|---|
| <input type="checkbox"/> Follow-up CT or LDCT | <input type="checkbox"/> Needle Biopsy (type of Needle Biopsy): |
| <input type="checkbox"/> PET | <input type="checkbox"/> Surgery |
| <input type="checkbox"/> Bronchoscopy (type of Bronchoscopy): | <input type="checkbox"/> Other (please specify): |

Date of Procedure (if scheduled): Physician Assessed Risk (%):

PHYSICIAN INFORMATION (REQUIRED)

Office Practice:		
Ordering Physician:		
Address:		
City:	State:	Zip Code:
Office Practice Primary Contact:	Phone:	Fax:
Office Practice Secondary Contact:	Phone:	Fax:
Test Result Delivery: <input type="checkbox"/> Encrypted Email <input type="checkbox"/> Fax <input type="checkbox"/> Copy Secondary Contact <input type="checkbox"/> Physician Portal		
Email:		

By checking any of these test delivery options, you are authorizing the electronic delivery of test results by Biodesix in accordance with the Health Insurance Portability and Accountability Act and the rules reflected in the HITECH Act.

BLOOD DRAW INSTRUCTIONS (REQUIRED)

Select the location of blood draw

- | | |
|---|---|
| <input type="checkbox"/> Coordinate Home Phlebotomy (Fax this form to 1.866.432.3338) | <input type="checkbox"/> Ambulatory Surgery Center |
| <input type="checkbox"/> In Office (non-hospital) | <input type="checkbox"/> Hospital (inpatient) |
| <input type="checkbox"/> Veteran's Affairs (VA) Facility | <input type="checkbox"/> Hospital (outpatient) |
| <input type="checkbox"/> Independent Lab (enter name): | <input type="checkbox"/> Independent Phlebotomist (enter name): |

For Phlebotomist Use Only

- I, the phlebotomist, verify that the enclosed specimen was collected and processed according to the protocol provided by Biodesix. I verify that this specimen is the specimen taken from the patient named on this form.

Initial: Date (MM|DD|YYYY):

AUTHORIZATION AND CERTIFICATION OF MEDICAL NECESSITY (REQUIRED)

Your signature constitutes a certification of medical necessity and intent to consider and use the results of the test(s) ordered. All of the information on this form is true and correct. You have obtained patient consent and authorize Biodesix to use and release the results and patient information for reimbursement purposes and as may be appropriate for additional clinical testing services.

Signature of treating physician or authorized representative: Date (MM|DD|YYYY):

Medicare Signature Requirements for providers define a valid signature as "handwritten or electronic". Please provide a wet ink or electronic signature on this form. If you are unable to do so, please contact Biodesix Customer Care at 1.866.432.5930.

INTERESTED IN ONLINE ORDERING AND TEST DELIVERY?

Contact Customer Care at 1.866.432.5930 to learn more about the Biodesix Physician Portal.



**CALCULATE RISK OF MALIGNANCY
AT NODULERISK.BIODESIX.COM**

1. Swensen SJ, Silverstein MD, Ilstrup DM, et al. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. *Arch Intern Med.* 1997; 157(8): 849-55.